Etanercept + methotrexate (DrugBank: Etanercept, Methotrexate)
15 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
15 | 封入体筋炎 | 0 |
28 | 全身性アミロイドーシス | 0 |
35 | 天疱瘡 | 0 |
38 | スティーヴンス・ジョンソン症候群 | 0 |
39 | 中毒性表皮壊死症 | 0 |
46 | 悪性関節リウマチ | 3 |
50 | 皮膚筋炎/多発性筋炎 | 0 |
53 | シェーグレン症候群 | 0 |
56 | ベーチェット病 | 0 |
60 | 再生不良性貧血 | 0 |
85 | 特発性間質性肺炎 | 0 |
228 | 閉塞性細気管支炎 | 0 |
271 | 強直性脊椎炎 | 0 |
285 | ファンコニ貧血 | 0 |
298 | 遺伝性膵炎 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03813771 (ClinicalTrials.gov) | March 2019 | 12/9/2018 | Targeted Treatment Early With Etanercept + Methotrexate vs.T2T Care for DMARD-naïve Early RA Patients Based on naïve T-cell Stratification | Targeted Treatment Early With Etanercept Plus Methotrexate Versus T2T Care for DMARD-naïve Early RA Patients. A Prospective, Longitudinal Cohort Study With Embedded Pilot Randomised Controlled Trial to Assess Treatment Rationalisation Based on naïve T-cell Stratification. | Rheumatoid Arthritis | Drug: Benepali;Drug: Sulfasalazine;Drug: Methotrexate;Drug: Hydroxychloroquine | University of Leeds | Samsung Bioepis Co., Ltd. | Not yet recruiting | 18 Years | N/A | All | 106 | Phase 4 | United Kingdom |
2 | NCT00783536 (ClinicalTrials.gov) | November 2008 | 29/10/2008 | A Multicenter Study to Compare the Efficacy and Safety of the Combination of Etanercept and Methotrexate in Treatment of Rheumatoid Arthritis | An Randomized, Open Label, Multicenter Study to Compare the Efficacy and Safety of the Combination of Etanercept and Methotrexate With DMARD Therapy in Subjects With Active Early Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: Etanercept + Methotrexate;Drug: DMARDS | Wyeth is now a wholly owned subsidiary of Pfizer | NULL | Withdrawn | 18 Years | 80 Years | Both | 402 | Phase 4 | Mexico |
3 | NCT00706797 (ClinicalTrials.gov) | September 2008 | 25/6/2008 | Study Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA Subjects | An Open-Label, Randomized Study to Evaluate the Radiographic Efficacy and Safety of Enbrel™ (Etanercept) Added to Methotrexate in Comparison With Usual Treatment in Subjects With Moderate Rheumatoid Arthritis Disease Activity | Rheumatoid Arthritis | Drug: etanercept (EnbrelTM);Drug: methotrexate | Wyeth is now a wholly owned subsidiary of Pfizer | NULL | Terminated | 18 Years | N/A | All | 141 | Phase 4 | Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;Turkey;United Kingdom;Austria;Croatia;United States |